RRM2B and neoplasm: Additionally, when analysing clinical outcome according to p53, p53R2, and clinical response to CRT in 24 patients who did not undergo surgery, the 1- and 3-year survival rates of the patients with p53 (−) and p53 (+) tumours were 55.4, 29.4 and 21.0, 0%, respectively (P=0.0095), p53R2 (−) and p53R2 (+) tumours were 62.9, 30.2 and 0, 0%, respectively (P=0.0043), and CR+PR and NC+PD tumours were 50.8, 27.1 and 16.7, 0% respectively, (P=0.0041) (Figure 3).